

NEWS RELEASE



April 28, 2020

Notification of MA Transfer Completion of Tadalafil Products

Nippon Shinyaku Co., Ltd. (Head office, Kyoto City; President, Shigenobu Maekawa) announced that the transfer of the Marketing Authorization (MA) in Japan for tadalafil products (Cialis® tablet, Adcirca® tablet and Zalutia® tablet) has been completed from Eli Lilly Japan K.K. (Head office, Kobe City; Representative Director and President, Simone Thomsen)

In Japan, Nippon Shinyaku has been marketing three brands of tadalafil, Cialis an agent for erectile dysfunction, Adcirca an agent for pulmonary arterial hypertension and Zalutia an agent for dysuria associated with benign prostatic hyperplasia, as a treatment option for patients in respective therapeutic fields.

Upon the MA transfer completion, Nippon Shinyaku has become a MA holder of these products and continues to provide information to promote the proper use of tadalafil products.

Nippon Shinyaku is investigating its plan to sell an Authorized Generic of Zalutia through its affiliate company, in order to maximize the Tadalafil business.

Contact

Corporate Communications Dept., Nippon Shinyaku Co., Ltd.

FAX: +81-75-321-9128